TP-03 is a topical ophthalmic formulation of lotilaner that, if approved, may offer treatment for millions of patients with Demodex blepharitis.1
Up to 25 million patients with Demodex blepharitis in the US have been left without an FDA-approved treatment.1-3
TP-03 may change that.
The active ingredient in TP-03 is lotilaner, a well-characterized antiparasitic agent that targets parasite-specific GABA-CI channels.1
1. Tarsus announces positive topline data from Saturn-2 Phase 3, the second pivotal trial of TP-03 for the treatment of Demodex blepharitis, and expects to file a new drug application this year. News release. Tarsus Pharmaceuticals, Inc; May 2, 2022. 2. Tarsus Pharmaceuticals, Inc. announces positive results of Saturn-1 pivotal trial evaluating TP-03 for the treatment of Demodex blepharitis. Tarsus Pharmaceuticals, Inc. Press release. July 21, 2021. 3. Sadri E, Yeu L, Trattler W, Holdbrook M, Baba S. The prevalence of collarettes and Demodex blepharitis in ophthalmology and optometry practices. Presented at: ASCRS 2021. July 24, 2021; Las Vegas, NV. 4. Wilson FA, Stimpson JP, Wang Y. Inconsistencies exist in national estimates of eye care services utilization in the United States. J Ophthalmol. Published online August 9, 2015. doi:10.1155/2015/435606
"*" indicates required fields